Podcasts about kallyope

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in the Pharma and Biotech world. The FDA's vaccine planning meeting was canceled due to disruptions caused by Robert F. Kennedy Jr. GSK's CEO Emma Walmsley received a pay increase to align with industry standards. Lilly invested $27 billion in US manufacturing after Trump's tariff threats. Regeneron scaled back approval goals for a lymphoma bispecific drug. Kallyope released disappointing data for an oral obesity candidate. Trilink offers mRNA designs for reliable performance. Congress reintroduced the EPIC Act to remove IRA's 'pill penalty'. Layoffs were announced at Lava and Ryvu, with new job opportunities in the life sciences industry available.

The average CEO changes jobs every seven years. Each time, she or he must build trust and credibility from scratch. Jay Galeota, President and CEO of Kallyope, shares his experience on leveraging the "secret sauce" in any organization–its people.

Josh Wolfe co-founded Lux Capital to support scientists and entrepreneurs who pursue counter-conventional solutions to the most vexing puzzles of our time in order to lead us into a brighter future. The more ambitious the project, the better—like, say, creating matter from light. Wolfe is a director at Shapeways, Strateos, Lux Research, Kallyope, CTRL-labs, Variant, and Varda, and helped lead Lux Capital's investments in Anduril, Planet, Echodyne, Clarifai, Authorea, Resilience, and Hadrian. He is a founding investor and board member with Bill Gates in Kymeta, which makes cutting-edge antennas for high-speed global satellite and space communications. In this presentation, Wolfe shares the principles that guide his entrepreneurship and investments, giving examples from companies he has founded and funded.

Synopsis: Josh Wolfe is the Co-Founder and Managing Partner of Lux Capital, a venture capital firm that invests in emerging science and technology ventures. Josh joins us for a discussion centered around investing in biotech. He discusses the arc of his career and the forces that led him to pursue a path at the intersection of science and finance. Josh also talks about the current state of biotech investing, trends he expects to see in the future, his advice to founder-led biotech companies, what he believes are the top three criteria for success for biotech companies, and his thoughts on the future of biotech. It's an illuminating conversation you won't want to miss. Biography: Josh co-founded Lux Capital to support scientists and entrepreneurs who pursue counter-conventional solutions to the most vexing puzzles of our time in order to lead us into a brighter future. The more ambitious the project, the better—like, say, creating matter from light. Josh is a Director at Shapeways, Strateos, Lux Research, Kallyope, CTRL-labs, Variant, and Varda, and helped lead the firm's investments in Anduril, Planet, Echodyne, Clarifai, Authorea, Resilience and Hadrian. He is a founding investor and board member with Bill Gates in Kymeta, making cutting-edge antennas for high-speed global satellite and space communications. Josh is a Westinghouse semi-finalist and published scientist. He previously worked in investment banking at Salomon Smith Barney and in capital markets at Merrill Lynch. In 2008 Josh co-founded and funded Kurion, a contrarian bet in the unlikely business of using advanced robotics and state-of-the-art engineering and chemistry to clean up nuclear waste. It was an unmet, inevitable need with no solution in sight. The company was among the first responders to the Fukushima Daiichi disaster. In February 2016, Veolia acquired Kurion for nearly $400 million—34 times Lux's total investment. Josh is a columnist with Forbes and Editor for the Forbes/Wolfe Emerging Tech Report. He has been invited to The White House and Capitol Hill to advise on nanotechnology and emerging technologies, and a lecturer at MIT, Harvard, Yale, Cornell, Columbia and NYU. He is a term member at The Council on Foreign Relations and Chairman of Coney Island Prep charter school, where he grew up in Brooklyn. He graduated from Cornell University with a B.S. in Economics and Finance.

Bloomberg Opinion columnist Barry Ritholtz interviews Josh Wolfe, co-founder and managing partner at Lux Capital and a director at Shapeways, Strateos, Lux Research, Kallyope, CTRL-labs and Variant. He is also a founding investor and board member with Bill Gates at Kymeta, which makes cutting-edge antennas for high-speed global satellite and space communications. A Westinghouse semi-finalist and a published scientist, Wolfe previously worked in investment banking at Salomon Smith Barney and in capital markets at Merrill Lynch. 

Podcast Notes Key Takeaways “Venture capital is all about investing in people who are inventing the future. The people who are inventing the future tend to be technologists, engineers, and scientists – you have to be able to speak their language.”In venture investing, 1-2 investments usually return the whole fundAbout a third of the investments will be total dudsAdvice for recent college grads interested in being an entrepreneur:“Build your brand, be differentiated, be indispensable, stay close to the money, find where the capital is flowing, and stay close to it.”Also read A LOT – “And be voracious in your reading. I think you have to be exposed to so many things. This allows you to develop your passion and then from your passion develop an expertise and be able to stand out.”Be good to people – you never know when you might need someoneThe single best trait of an entrepreneur is somebody that can tell a story“They are the people that recruit talent. They are the people that can raise money. They are the people that garner attention and win deals and that is what makes the venture capital business.” Josh’s biggest failures are the things that have the permanence of regret“Choices I made, or relationships that I under-invested in, or people that I didn’t spend enough time with who passed… those to me are the biggest failures”You can lose money in an investment and make it right back in another, but you won’t always get that second chance if you lose a friendship/relationshipRead the full notes @ podcastnotes.orgBloomberg Opinion columnist Barry Ritholtz interviews Josh Wolfe, co-founder and managing partner at Lux Capital and a director at Shapeways, Strateos, Lux Research, Kallyope, CTRL-labs and Variant. He is also a founding investor and board member with Bill Gates at Kymeta, which makes cutting-edge antennas for high-speed global satellite and space communications. A Westinghouse semi-finalist and a published scientist, Wolfe previously worked in investment banking at Salomon Smith Barney and in capital markets at Merrill Lynch. 

Nancy Thornberry, CEO of Kallyope, talks with Michelle Maskaly and Christen Harm about New York City as an emerging hotspot for biotech incubators, and the challenges and opportunities related to space, location, recruitment, and funding.

Today in FirstWord:

Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotechs and authored a manual nicknamed 'the bible of cloning.' His conversation with Nature Biotechnology covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor. See acast.com/privacy for privacy and opt-out information.